On July 25, 2025 Omeros Corporation (Nasdaq: OMER) ("Omeros" or the "Company") reported that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering (Press release, Omeros, JUL 25, 2025, View Source [SID1234654528]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the securities purchase agreement, the Company has agreed to sell 5,365,853 shares of its common stock at a price of $4.10 per share, which represents a premium of approximately 14% to the closing price of the Company’s common stock on the date of the securities purchase agreement.
The gross proceeds to the Company from the registered direct offering are estimated to be approximately $22 million, before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about July 28, 2025, subject to the satisfaction of customary closing conditions.
The proposed offering of the common stock described above is being offered by the Company pursuant to a "shelf" Registration Statement on Form S-3 (File No. 333-268269) filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on November 17, 2022, and the accompanying prospectus contained therein.
The offering is being made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement.
D. Boral Capital LLC is acting as exclusive placement agent for the offering.
Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.